Asia
Eisai Co., Ltd. announced that in the 8th meeting of the Data Safety Monitoring Board for the global Phase III clinical studies on the investigational oral BACE inhibitor elenbecestat in early Alzheimer’s disease, the DSMB reviewed safety data including the potential for decline in cognition, and recommended the continuation of the studies.
AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo Company for trastuzumab deruxtecan (DS-8201).
Seattle Genetics and Tokyo-based Astellas Pharma announced positive topline data from the first cohort of its Phase II EV-201 trial.
Abu Dhabi Smart Solutions and Services Authority (ADSSSA) delivers smart government services on one digital platform to streamline and enrich customer experience
New cost competitive wafer-to-wafer layer transfer process delivers low power, increased yield and higher interconnection density and speed
BioSpace takes a quick look at some of the news coming from biotech and pharma companies from across Europe and Asia.
On March 26, AbbVie announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved its Skyrizi (risankizumab) for plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults who haven’t responded to conventional therapies.
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced that it has acquired marketing approval for Revcovi 2.4 mg for intramuscular injection [Elapegademase] from the Ministry of Health, Labor and Welfare .
YL Biolologics Ltd., Yoshindo Inc. and Teijin Ltd. have announced that on March 26, 2019, YL Biologics obtained manufacturing and sales approval for Etanercept biosimilar, an agent for anti-rheumatoid arthritis and polyarticular-course juvenile idiopathic arthritis which YL Biologics has developed globally.
Early-Stage Business Accelerator to Empower Local MedTech Innovation and Enhance Medtronic China’s Industry Leadership
PRESS RELEASES